BR0306820A - Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus - Google Patents

Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus

Info

Publication number
BR0306820A
BR0306820A BR0306820-0A BR0306820A BR0306820A BR 0306820 A BR0306820 A BR 0306820A BR 0306820 A BR0306820 A BR 0306820A BR 0306820 A BR0306820 A BR 0306820A
Authority
BR
Brazil
Prior art keywords
cox
inhibitors
treatment
combination
antiviral agents
Prior art date
Application number
BR0306820-0A
Other languages
English (en)
Inventor
Kong Teck Chong
Original Assignee
Pharmacia & Up John Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Up John Company filed Critical Pharmacia & Up John Company
Publication of BR0306820A publication Critical patent/BR0306820A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/027—Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE INIBIDORES COX-2 EM COMBINAçãO COM AGENTES ANTIVIRAIS PARA O TRATAMENTO DE INFECçõES DE PAPILOMAVìRUS". A presente invenção refere-se a terapias combinadas para tratar o papilomavírus.
BR0306820-0A 2002-01-10 2003-01-10 Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus BR0306820A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34755002P 2002-01-10 2002-01-10
PCT/US2003/000016 WO2003059347A1 (en) 2002-01-10 2003-01-10 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

Publications (1)

Publication Number Publication Date
BR0306820A true BR0306820A (pt) 2004-12-07

Family

ID=23364195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306820-0A BR0306820A (pt) 2002-01-10 2003-01-10 Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus

Country Status (16)

Country Link
US (1) US20030211163A1 (pt)
EP (1) EP1463500A1 (pt)
JP (1) JP2005519061A (pt)
KR (1) KR20040072720A (pt)
CN (1) CN1697654A (pt)
AU (1) AU2003201811A1 (pt)
BR (1) BR0306820A (pt)
CA (1) CA2472459A1 (pt)
CO (1) CO5590913A2 (pt)
IL (1) IL162726A0 (pt)
MX (1) MXPA04006572A (pt)
NO (1) NO20043313L (pt)
PL (1) PL371252A1 (pt)
RU (1) RU2004121147A (pt)
WO (1) WO2003059347A1 (pt)
ZA (1) ZA200404881B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP1206554B2 (en) 1999-08-25 2010-10-20 Allergan, Inc. Activatable recombinant neurotoxins
US20040152752A1 (en) * 2002-05-30 2004-08-05 Chong Kong Teck Treatment for human papillomavirus
CN1726018A (zh) * 2002-12-19 2006-01-25 法玛西雅公司 使用环加氧酶－2选择性抑制剂或环加氧酶－2抑制剂联合抗病毒剂治疗疱疹病毒感染的方法和组合物
WO2005055932A2 (en) 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
PE20061303A1 (es) * 2005-03-30 2006-12-07 Astion Dev As Composicion farmaceutica que comprende oxaprozina
CN104906105A (zh) * 2005-05-18 2015-09-16 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
KR100644968B1 (ko) * 2005-10-28 2006-11-14 한국과학기술연구원 생체적합성 실리콘 나노입자의 제조 방법
WO2008036858A2 (en) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US9675544B2 (en) 2008-01-22 2017-06-13 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CA2721586A1 (en) * 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
IL192335A0 (en) * 2008-06-19 2011-08-01 Avivi Easy Life Ltd Antiviral compounds
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
US20130203742A1 (en) 2012-02-06 2013-08-08 William L. Pridgen Valaciclovir and meloxicam combination therapy for functional somatic syndromes
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
CN105906496A (zh) * 2016-05-16 2016-08-31 苏州毕诺佳医药技术有限公司 一种阿昔洛韦的药物组合物及其医药用途
CN117860740A (zh) * 2020-12-28 2024-04-12 中以海德人工智能药物研发股份有限公司 一种用于治疗或预防病毒性肝炎的药物组合物及其应用
EP4340884A1 (en) * 2021-05-19 2024-03-27 University of Miami Treatment of infections in and around the eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
CA2249009C (en) * 1996-04-12 2003-09-16 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
EP1039914A4 (en) * 1997-12-17 2007-06-27 Cornell Res Foundation Inc CYCLOOXYGENASE-2 INHIBITION
TR200103271T2 (tr) * 1999-05-14 2002-06-21 The Regents Of The University Of California İnflamasyon aracılığıyla gerçekleşen infeksiyon için anti-inflamatuar tedavi.
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway

Also Published As

Publication number Publication date
ZA200404881B (en) 2005-08-31
US20030211163A1 (en) 2003-11-13
RU2004121147A (ru) 2005-04-10
CA2472459A1 (en) 2003-07-24
JP2005519061A (ja) 2005-06-30
PL371252A1 (en) 2005-06-13
CN1697654A (zh) 2005-11-16
IL162726A0 (en) 2005-11-20
KR20040072720A (ko) 2004-08-18
WO2003059347A1 (en) 2003-07-24
CO5590913A2 (es) 2005-12-30
EP1463500A1 (en) 2004-10-06
MXPA04006572A (es) 2005-11-04
AU2003201811A1 (en) 2003-07-30
NO20043313L (no) 2004-10-08

Similar Documents

Publication Publication Date Title
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
MY137757A (en) Therapeutic treatment
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
BRPI0411900A (pt) compostos antivirais e métodos
SG145699A1 (en) Pyridazine derivatives and their use as therapeutic agents
IL158559A0 (en) Acne treatment
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
IL173188A0 (en) Use of alcohol-oxyalkyates in the form of adjuvants for benzamidoxime gungicidal derivatives, appropriate agents and kits
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
BR0314844A (pt) Novo composto
BR0314843A (pt) Novo composto
ATE256461T1 (de) Benutzung von comt-inhibitoren als analgetika
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
BR0002640A (pt) Uso de simeticona para tratar colite ulcerativa
MY140194A (en) Novel fusidic acid derivatives
DE60219788D1 (de) Tetrazyklische verbindungen als pde5-inhibitoren
BRPI0406985A (pt) Terapia de combinação de hcv
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.